NEW YORK, Feb. 4, 2025 -- Pomerantz LLP is investigating claims on behalf of investors of Reckitt Benckiser Group plc ("Reckitt" or the "Company") (OTCMKTS:RBGLY). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
The investigation concerns whether Reckitt and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On March 15, 2024, an Illinois jury returned a $60 million verdict against Reckitt in a lawsuit finding that Reckitt's Mead Johnson Nutrition unit failed to adequately disclose the risks of necrotizing enterocolitis in its cow-milk-based Enfamil baby formula. Following the verdict, Reckitt's American depositary receipt ("ADR") price fell $1.87 per ADR, or 14.05%, to close at $11.44 per ADR on March 15, 2024.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Danielle Peyton
Pomerantz LLP
dpeyton@pomlaw.com
646-581-9980 ext. 7980
This News is brought to you by Qube Mark, your trusted source for the latest updates and insights in marketing technology. Stay tuned for more groundbreaking innovations in the world of technology.
